Pharma Sector

Indian benchmark indices extended their winning streak for a fifth consecutive session on November 4, 2026, with Sensex rising 383.55 points (0.50%) to 77,301.40 and Nifty advancing 149.75 points (0.63%) to 23,960.60. Late-session buying, continued FII inflows, softer crude oil prices and positive global cues supported the rally. Nifty Media, Realty and Metal led sectoral gains, while Bharat Electronics, Adani Enterprises and Titan emerged among the notable gainers. However, IT stocks remained under pressure, with TCS, HCLTech and Infosys among the top losers.

Indian benchmark indices extended their gains for the second consecutive session on November 3, 2026. Sensex rallied 1,225.07 points (1.62%) to close at 76,917.85, while Nifty advanced 370.05 points (1.58%) to 23,810.85. FMCG, Realty and Private Bank stocks led the rally, with Nestle India, Tata Consumer Products and Asian Paints among the top gainers. Easing crude oil prices, continued FII buying and improved global sentiment supported the market, while PSU Banks, Metals and Energy stocks ended lower.

Indian stock markets ended sharply higher on November 2, 2026, with Sensex rising 1.66% to 75,692.78 and Nifty gaining 1.68% to 23,440.80. Reliance Industries surged 11.60% following record Q2 FY27 earnings, while Energy, Infrastructure and Metal stocks led sectoral gains. Softer crude oil prices, foreign fund inflows and positive global cues further supported market sentiment.

Reliance Industry Ltd. (RIL) stock rose 6.36% on Monday early trading session after posting record Q2 FY27 numbers. Driven by strong refining margins from the Oil to Chemicals (O2C) segment and steady growth from its Jio Platforms, investors have been optimistic. Global broking firm Goldman Sachs has retained its Buy recommendation on the stock, with a target price of Rs 1840, which shows upside potential of around 58%.

Laurus Labs shares gained 4.94% after the company reported a 126% YoY rise in Q2 FY27 net profit to ₹441.48 crore. Revenue increased 33%, while EBITDA margin expanded to 34.5%.

Piramal Pharma shares rose 13.80% on October 28 after the company reported a return to profitability in Q2 FY27, 28% year-on-year revenue growth and a significant improvement in EBITDA margins. The company raised its FY27 revenue growth outlook to 19%–20%.

Indian stock markets ended lower for the third consecutive session on October 22, with the Sensex declining 460 points and the Nifty slipping below 22,700. Media, FMCG, IT and energy stocks led sectoral losses, while rising Brent crude prices and a sell-off across Asian markets added to investor concerns.

Sensex fell 876 points to 73,852.90 and Nifty declined 1.11% to 22,888.95 on October 19, 2026. Banking and IT stocks led losses amid earnings concerns, elevated crude oil prices and foreign investor outflows.

Cupid shares hit a record high of ₹344.90 after entering the Nifty Smallcap 250 index. Nuvama estimates potential passive inflows of around $10 million, while strong Q1 earnings and upgraded guidance add to investor interest.

The Indian stock market is under pressure as geopolitical tensions, rising crude oil prices, higher US Treasury yields, rupee weakness and foreign investor selling trigger a broad-based sell-off in Nifty and Sensex.